COMMUNIQUÉS West-GlobeNewswire

-
Teva Releases Q2 2025 Aide Memoire
26/06/2025 -
Kane Biotech Announces Conversion of Demand Loan from Insider into an Unsecured Convertible Debenture and Annual General Meeting Voting Results
26/06/2025 -
Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
26/06/2025 -
Extendicare Announces Renewal of Normal Course Issuer Bid
26/06/2025 -
Earth Science Tech, Inc. Reports Fiscal Year-End Results for March 31, 2025, with Revenue Exceeding $33.1 Million and Net Profit of $3.2 Million
27/06/2025 -
PetVivo Sets Fiscal Fourth Quarter 2025 Conference Call for Monday, June 30 at 5:00 p.m. ET
26/06/2025 -
Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company
26/06/2025 -
Indacloud Unveils Top Premium THCA Flower Line
26/06/2025 -
EVA Pharma and BioPharma Town - Qiantang District, Hangzhou Sign a Strategic Cooperation Agreement
26/06/2025 -
INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th
26/06/2025 -
STENTiT Enrolls First Patient in Clinical Trial Evaluating a Novel Stent with Regenerative Properties to Support Limb Preservation
26/06/2025 -
Food-Derived Longevity Supplement Primeadine® GF Launches at Erewhon
26/06/2025 -
Press release: Transparency Notification from Shareholders
26/06/2025 -
XORTX Announces USD $925,000 Private Placement
26/06/2025 -
CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline
26/06/2025 -
Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH
26/06/2025 -
Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection
26/06/2025 -
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary
26/06/2025 -
ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
26/06/2025
Pages